Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Synthesis of Novel Nano-Radiotracer for In-Vivo Bone Imaging: 99Mtc- Citric Acid Based Peg Dendrimer and Its Conjugation With Alendronate Publisher



Davoodikia B1 ; Pirali Hamedani M2 ; Saffari M3 ; Esmaeil Sadat Ebrahimi S2 ; Seyyed Hamzeh M2 ; Hashemi S2 ; Shafiee Ardestani M2 ; Masoumeh Ghoreishi S4
Authors
Show Affiliations
Authors Affiliations
  1. 1. School of pharmacy international campus Tehran university of medical sciences, Tehran, Iran
  2. 2. Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Branch of Pharmaceutical Sciences, Islamic Azad University, Tehran, Iran.Department of Pharmaceutics & Medical Nanotechnology
  4. 4. Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran

Source: Arabian Journal of Chemistry Published:2022


Abstract

Bone scan is the test that guide physician to diagnose diseases in the bone at the early stage, to prevent metastases to other organs. In this study, citric acid dendrimer conjugation with alendronate was synthesized. Obtained product was confirmed by FT-IR and TEM. Cytotoxicity assay at different concentrations showed no toxicity on normal cell line compared to control group. Radiolabeling process was optimized by Box-Behnken software which is a computational method to determine optimum of important radiolabeling parameters. Optimized parameter for reducing agent, dendrimer-G2-alendronate, and time for shaking was 1 mg, 12.3 mg, and 25 min respectively. For determination of in-vivo accumulation of 99mTc-dendrimer-G2-alendronate, SPECT imaging was done. Images showed high accumulation of radio-tracer in the skeletal compared to 99mTc-MDP which is the frequent bone scan agent. All in all, obtained results confirmed our hypothesis that the dendrimer-G2-alendronate can be noteworthy nano-radiopharmaceuticals to bone cancer imaging at early stage. © 2022 The Author(s)